Monday, August 17, 2015

Idebenone Protects against Oxidized Low Density Lipoprotein Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via GSK3β/β-catenin signaling pathways

Pengfei Lin, Junling Liu, Ming Ren, Kunqian Ji, Ling Li, Bin Zhang, Yaoqin Gong, Chuanzhu Yan, Idebenone Protects against Oxidized Low Density Lipoprotein Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via GSK3β/β-catenin signaling pathways, Biochemical and Biophysical Research Communications, Available online 15 August 2015, ISSN 0006-291X, http://dx.doi.org/10.1016/j.bbrc.2015.08.058.

Intel just open sourced Stephen Hawking’s speech system and it’s a .NET 4.5 WinForms app that you can try for yourself

Mansib Rahman, Canadian Developer Connection. 14 Aug 2015

As we all know, the venerable physicist Professor Stephen Hawking is unable to talk as he is afflicted with ALS and thus relies on a computer system to communicate. In 2011, his condition was deteriorating so badly that he could best communicate at a rate of only 2 words per minute. He reached out to Alan Moore at Intel and asked if Intel could come up with new technology to help his plight.

Well, what are you waiting for? You can try all this out for yourself. Visit the software's Github release page to get the installer.


Nrf2—a therapeutic target for the treatment of neurodegenerative diseases

Nrf2—a therapeutic target for the treatment of neurodegenerative diseases. Delinda A. Johnson, Jeffrey A. Johnson, Free Radical Biology and Medicine, Available online 14 August 2015, Page FRBMD1500535, ISSN 0891-5849, http://dx.doi.org/10.1016/j.freeradbiomed.2015.07.147.

The brain is very sensitive to changes in redox status; thus maintaining redox homeostasis in the brain is critical for the prevention of accumulating oxidative damage. Recently, a clinical trial using RTA 408 was initiated for Friedreich’s ataxia, a neurodegenerative condition responsible for cerebellar ataxia due to impaired production of the protein frataxin leading to profound deficiencies in mitochondrial respiration (ClinicalTrials.gov Identifier NCT02255435).